XML 103 R66.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business combinations (Details Narrative) - BRL (R$)
R$ in Thousands
 12 Months Ended
Jan. 02, 2023
May 23, 2022
Apr. 05, 2022
Mar. 04, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
IfrsStatementLineItems [Line Items]              
Net revenue         R$ 2,875,913 R$ 2,329,057 R$ 1,719,371
Income loss before income taxes         429,582 428,433 R$ 273,462
Acquisition Of Del Rey [Member]              
IfrsStatementLineItems [Line Items]              
Acquired share capital 100.00%            
Acquired purchase price The original aggregate purchase price of R$832,236 was adjusted by R$16,000, in favor of the Company, to R$816,236 comprised by: i) R$809,000 of which R$575,000 was paid in cash on the transaction closing date, and R$234,000 is payable in cash in three annual installments, respectively, of R$134,000 in January 2024, R$50,000 in January 2025 and R$50,000 in January 2026, adjusted by the SELIC rate; and ii) offer of AFYA’s digital solutions free of charge until December 31, 2030, for students of medicine of universities owned by the sellers which are not part of the transaction. The fair value of this service was estimated at R$7,236 at the acquisition date. There are 84 additional seats still pending approval which, if approved by MEC, will result in a potential additional payment of up to R$105,000. Given the future event that will trigger the potential payout is not under the Company’s control, the probability of such payout cannot be reliably estimated and accordingly the contingent consideration was not measured at the acquisition date. Should the additional seats be approved, it will result in additional licenses, which will be measured accordingly if and when approved.            
Transaction costs R$ 12,332            
Net revenue         240,107    
Income loss before income taxes         82,147    
Alem Da Medicina [member]              
IfrsStatementLineItems [Line Items]              
Acquired share capital       100.00%      
Acquired purchase price       The aggregate purchase price of R$26,789 is comprised by: i) R$14,952 paid in cash on the transaction closing date; ii) an earn-out (“contingent consideration”) of up to R$19,200 is payable in connection with revenue target achievements for 2023 and 2024; and iii) price adjustment related to net debt of R$763 in favor of selling shareholders. The contingent consideration of R$11,074 is based on the present value of the obligation considering the facts and circumstances at the acquisition date.      
Transaction costs       R$ 227      
Net revenue       12,859      
Income loss before income taxes       R$ 1,448      
Increase in revenue           2,529  
Increase in income before income taxes           867  
Acquisition Of Cardio Papers [Member]              
IfrsStatementLineItems [Line Items]              
Acquired share capital     100.00%        
Acquired purchase price     The aggregate purchase price of R$42,013 is comprised by: i) R$34,924 paid in cash on the transaction closing date; ii) an earn-out (“contingent consideration”) of up of R$15,000 is payable in connection with revenue target achievements for 2023 and 2024 and other goals; and iii) price adjustment related to net debt of R$333 in favor of Afya Brazil. The contingent consideration of R$7,422 is based on the present value of the obligation considering the facts and circumstances at the acquisition date.        
Transaction costs     R$ 274        
Cardio Papers [Member]              
IfrsStatementLineItems [Line Items]              
Net revenue     9,934        
Income loss before income taxes     R$ 2,352        
Increase in revenue           2,117  
Decrease in income before income taxes           R$ 2,041  
Acquisition Of Glic [Member]              
IfrsStatementLineItems [Line Items]              
Acquired share capital   100.00%          
Acquired purchase price   The aggregate purchase price of R$30,597 is comprised by: i) R$21,602 paid in cash on the transaction closing date and ii) an earn-out (“contingent consideration”) of up of R$12,000 is payable in connection with revenue target achievements for 2023 and 2024 and product development goals. The contingent consideration of R$8,995 is based on the present value of the obligation considering the facts and circumstances at the acquisition date.          
Transaction costs   R$ 222          
Glic [member]              
IfrsStatementLineItems [Line Items]              
Net revenue   389          
Income loss before income taxes   R$ 1,539          
Increase in revenue         173    
Decrease in income before income taxes         R$ 700